Consensus Crossject

Stocks

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris 16:50:39 15/10/2026 +03			5-day change	1st Jan Change
1.310 ^EUR	-0.76%		+1.08%	-40.18%

10-12	Crossject: No market launch of Zepizure before H127 at best	AL
09-25	Crossject: H126. Quid novi sub sole? Not much.	AL

Evolution of the Average Target: Crossject

Evolution of the Target Price: Crossject

Changes in Analyst Recommendations: Crossject

05daa715f6edfa2b.DzP1NH-Q7Fz_DWJIPpqFjvqbOD8_P_uXwN0eyZ1_VBA.TkmEWzP7unGtXFEKB_vq2rL1cG5wU5bOkeQns68XC2hDe7Z1Fde5CctGAQ~6fa011253377308b8df3749db88869a8

Analysts' recommendations: Crossject

10-12	Crossject: No market launch of Zepizure before H127 at best	AL
09-25	Crossject: H126. Quid novi sub sole? Not much.	AL
05-26	Crossject: The last round of financing?	AL
03-30	Crossject: Integrating the FY25 numbers	AL
03-25	Crossject: FY25 results: no big change.	AL
11-17	Crossject: Yet another round of financing	AL
25/06/25	Crossject: Invest Securities Upgrades to 'Buy' Following Successful Capital Increase
09/06/25	Crossject: Here we are for the announced capital increase	AL
21/05/25	Crossject: Another capital increase in the pipe…	AL
07/05/25	Crossject: Back to life?	AL
30/03/25	Crossject: Integrating the FY24 numbers.	AL
27/03/25	Crossject: FY24 and outlook: long is the road…	AL
10/02/25	Crossject: A complex financing given the amounts involved	AL
11/12/24	Crossject: An unsurprising additional financing round.	AL
07/10/24	Crossject: H1 24: not yet meaningful	AL
25/09/24	Crossject: H1 24: no real surprise, but a glimpse of disappointment	AL
17/07/24	Crossject: We are still believers	AL
05/06/24	Crossject: Success of the capital increase	AL
02/05/24	Crossject: We welcome the securing of the group’s financial needs	AL
03/04/24	Crossject: Patience is a virtue… hopefully	AL
28/02/24	Crossject: Invest Securities slightly reduces its target
28/02/24	Crossject: Securing the financing needs	AL
08/02/24	Crossject: No news is not always good news...	AL
06/01/24	Crossject : Marketing initiative in the US	AL
03/01/24	Crossject : A new distribution agreement in Northern Europe	AL

More recommendations

Drug Delivery Systems

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
CROSSJECT	-	+233.33%
ABBOTT LABORATORIES		+17.23%
MEDTRONIC PLC		+10.79%
STRYKER CORPORATION		+28.76%
ESSILORLUXOTTICA		+51.22%
CENCORA, INC.		+10.11%
HOYA CORPORATION		+18.9%
BECTON, DICKINSON AND COMPANY		+2.75%
IDEXX LABORATORIES, INC.		+32.57%
DEXCOM, INC.		+15.56%
Average		+42.12%
Weighted average by Cap.		+20.73%